GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
I

ITonis ITNS · USD

Health Care · US listing · 🇺🇸 United States

Compare

0.00

—

Close of 4 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Price performance

Chart by TradingView, with its own licensed prices

ITonis — daily ITNS Delayed
Market value
$609,364
Last close × shares
Volume
6.3k
Shares, 4 Nov 2026

About ITonis

Its shares trade under the ticker ITNS. It has been listed since 21 February 2007. In the fiscal year to 30 November 2025, it reported revenue of $153 and a net loss of $11,322. At that date it held total assets of $136,401 and shareholders' equity of −$1.1m.

Itonis, Inc. engages in the distribution of its homeopathic anti-nausea product to the medical and pharmaceutical industry. The company is headquartered in Lake Forest, California. The company went IPO on 2007-02-21. The Company, through the Itonis Pharmaceuticals division, produces and markets over the counter and prescription homeopathic preparations to treat both common ailments and chronic diseases. The Company’s Emesyl nausea relief product focuses on the general public who suffers from nausea. Emesyl products are available for purchase at https://www.amazon.com and www.Emesyl.com. The firm's subsidiaries include Itonis Holdings, Inc. and Paramount Discoveries, Inc.

Figures and description from our data supplier, not checked against the company's own report.

More about ITonis →

Latest on ITonis

Our reporting

We have not reported on ITonis yet.

Other Health Care listings

Scenario calculator

Try your own numbers. This is arithmetic, not a forecast.

Interactive

Gain or loss

—

Return

—

Leaves out fees, taxes and financing.

Frequently asked questions

What is ITonis's ticker?

ITonis trades as ITNS on its US listing, under ISIN US4657331033.

What was ITonis's last closing price?

0.00 on 4 Nov 2026. The figure is in USD and is never converted.

Sources and methodology

Chart
TradingView
Close and company data
Our data supplier
News
Our reporting

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.